◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › DRUG

Bright Minds Biosciences Inc. (DRUG) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-25

Bright Minds Biosciences Inc. (DRUG) operates in the Biotechnology industry and is headquartered in New York, United States with about 26 employees. Its market capitalization is roughly $700 million. In the fiscal year ended 2025-09-30, DRUG reported $0M in revenue and ($12M) in net income.

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States.

Interactive charts & full statements →

DRUG Revenue & Earnings History — Annual Income Statement

Income statement2025-09-302024-09-302023-09-302022-09-302021-09-30
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($14M)($3M)($7M)($15M)
Net Income($12M)($3M)($7M)($15M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DRUG Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($15M)($7M)($6M)($3M)($3M)
Net Income($10M)($8M)($4M)($5M)($3M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DRUG Free Cash Flow History

DRUG Balance Sheet History

Balance sheet2025-09-302024-09-302023-09-302022-09-302021-09-30
Total Assets$84M$6M$7M$12M
Total Liabilities$2M$1M$0M$2M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive DRUG viewer.

Other Companies in Biotechnology

← DRTSAll stocksDRVN →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.